Krystal Biotech, Inc. (NASDAQ:KRYS) Short Interest Down 8.9% in December

Krystal Biotech, Inc. (NASDAQ:KRYS) saw a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalling 3,370,000 shares, a decrease of 8.9% from the December 15th total of 3,700,000 shares. Based on an average trading volume of 247,300 shares, the days-to-cover ratio is currently 13.6 days.

Krystal Biotech Price Performance

NASDAQ:KRYS opened at $148.39 on Friday. The firm has a 50-day moving average of $170.98 and a two-hundred day moving average of $182.15. The stock has a market cap of $4.27 billion, a P/E ratio of 83.84 and a beta of 0.85. Krystal Biotech has a 1-year low of $107.50 and a 1-year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The firm had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. During the same quarter in the prior year, the business posted ($0.67) earnings per share. Krystal Biotech’s revenue for the quarter was up 879.9% on a year-over-year basis. As a group, equities analysts expect that Krystal Biotech will post 3.03 earnings per share for the current year.

Analyst Ratings Changes

KRYS has been the topic of a number of research reports. Citigroup raised their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Chardan Capital reissued a “buy” rating and issued a $212.00 price objective on shares of Krystal Biotech in a research report on Wednesday, December 18th. Finally, HC Wainwright restated a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research note on Wednesday, December 18th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $206.67.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the transaction, the insider now directly owns 1,475,882 shares of the company’s stock, valued at $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 14.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Krystal Biotech

Several institutional investors and hedge funds have recently made changes to their positions in KRYS. Dimensional Fund Advisors LP increased its stake in shares of Krystal Biotech by 1.3% in the second quarter. Dimensional Fund Advisors LP now owns 580,452 shares of the company’s stock worth $106,593,000 after buying an additional 7,537 shares during the last quarter. Mutual of America Capital Management LLC grew its holdings in Krystal Biotech by 9.2% during the 2nd quarter. Mutual of America Capital Management LLC now owns 37,324 shares of the company’s stock worth $6,854,000 after acquiring an additional 3,135 shares in the last quarter. Amalgamated Bank increased its position in shares of Krystal Biotech by 937.9% in the 2nd quarter. Amalgamated Bank now owns 7,577 shares of the company’s stock worth $1,391,000 after purchasing an additional 6,847 shares during the last quarter. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Krystal Biotech in the 2nd quarter valued at about $252,000. Finally, Sei Investments Co. lifted its position in shares of Krystal Biotech by 18.9% during the second quarter. Sei Investments Co. now owns 40,115 shares of the company’s stock worth $7,367,000 after purchasing an additional 6,363 shares during the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).